1Srefan N, Sari M, Eckardt T, et al. Mechanisms of estrogen action [J]. Physiological Res, 2001,81 (4): 1536-1566.
2Lim SK, Won Y J, Lee HC, et al. A PCR analysis of ER-α and ER-β mRNA abundance in rats and the effect of ovariectomy [J ]. J Bone Miner Rev, 1999,14(7): 1189-1196.
3Kobayashi N, Fujino T, Shirogane T, et al. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen [J ]. Maturitas, 2002, 41 ( 3 ): 193-201.
4Vidal O, Kindblom LG, Ohlesson C. Expression and localization of estrogen receptor-beta in murine and human bone[J ]. J Bone Miner Rev, 1999,14(6) :923-929.
6Ke HZ, Crawford DT, Qi H, et al. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats [J ]. Bone, 1999,24(1):41-47.
7Cosman F and Lindsay R. Selective estrogen receptor modulators:clinical spectrum [J ]. Endocr Rev, 1999,20 (3): 418-434.
8Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene,hormone replacement therapy, and placebo on bone turnover inpostmenopausal women[ J ]. Osteoporos Int, 2003, 14 ( 10 ): 814-22.
9Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly [J ]. Arch Intern Med, 2003,163 (18):2237-46.
10D'Amelio P, Muratore M, Tinelli F, et al. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women[ J ]. Int J Tissue React, 2003,25 (2): 73-8.
